icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TEZSPIRE (Tézépélumab).
See also
Décision d'accès précoce
22/12/2022
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
6Eg94ekHBX1SuR5t